Cargando…

The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2

The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamous, Yahya F, Alhomoud, Dalal A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588549/
https://www.ncbi.nlm.nih.gov/pubmed/37868494
http://dx.doi.org/10.7759/cureus.45602
_version_ 1785123607182049280
author Jamous, Yahya F
Alhomoud, Dalal A
author_facet Jamous, Yahya F
Alhomoud, Dalal A
author_sort Jamous, Yahya F
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently. Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. The clinical data reviewed in this article demonstrate that the currently authorized Moderna and Pfizer-BioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.
format Online
Article
Text
id pubmed-10588549
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105885492023-10-21 The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2 Jamous, Yahya F Alhomoud, Dalal A Cureus Epidemiology/Public Health The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently. Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. The clinical data reviewed in this article demonstrate that the currently authorized Moderna and Pfizer-BioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. Cureus 2023-09-20 /pmc/articles/PMC10588549/ /pubmed/37868494 http://dx.doi.org/10.7759/cureus.45602 Text en Copyright © 2023, Jamous et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Epidemiology/Public Health
Jamous, Yahya F
Alhomoud, Dalal A
The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
title The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
title_full The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
title_fullStr The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
title_full_unstemmed The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
title_short The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
title_sort safety and effectiveness of mrna vaccines against sars-cov-2
topic Epidemiology/Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588549/
https://www.ncbi.nlm.nih.gov/pubmed/37868494
http://dx.doi.org/10.7759/cureus.45602
work_keys_str_mv AT jamousyahyaf thesafetyandeffectivenessofmrnavaccinesagainstsarscov2
AT alhomouddalala thesafetyandeffectivenessofmrnavaccinesagainstsarscov2
AT jamousyahyaf safetyandeffectivenessofmrnavaccinesagainstsarscov2
AT alhomouddalala safetyandeffectivenessofmrnavaccinesagainstsarscov2